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Background
This study aims to evaluate the reconstitution of NK cell
functions in HIV/TB co-infected patients developing
IRIS versus those not having IRIS after TB and anti-
retroviral treatment initiation.
Methods
(i) 138 HIV+/TB+ patients enrolled in the CAMELIA
trial (ANRS 1295-CIPRA/KH001-DAIDS-ES ID10425)
in Cambodia and 36 HIV+ patients with CD4
+ T cells
< 200/mm
3 included (ii) NK cells repertoire analysis by
immuno-staining in whole blood and, (iii) NK cells
degranulation activity and cytokine production by
CD107a essay with and without stimulation. After start-
ing of TB therapy in HIV+/TB+ patients, the time
points were weeks 2, 8, 14 and 34. Half of the patients
started HAART at week 2 and the other half at week 8.
The time point of HIV+/TB- were week 0 and 8. The
results obtained at baseline and following HAART are
presented.
Results
37/138 HIV+/TB+ patients developed IRIS. 33 IRIS, 67
non IRIS and 36 HIV+/TB- were available for CD107a
degranulation and IFNg production analysis and 32 IRIS,
78 non IRIS and 36 HIV+/TB- for NK cell repertoires
analysis. At baseline, CD107a degranulation was lower in
HIV+/TB+ (IRIS and non IRIS) than in HIV+/TB- (med-
ian 8.88 and 6.62 vs 12.81, p=0.008; p<0.0001). The IFNg
production was also lower in HIV+/TB+ (median 1.91
and 2.46 vs 6.55, p<0.001). From baseline to 6 weeks of
HAART, CD107a degranulation in HIV+/TB+ (IRIS and
non IRIS) were lower than 8 weeks treated HIV+/TB-
(0.09 and 0.51 vs 7.53; p=0.04 and p=0.002, respectively),
whereas the IFNg production was not different (p>0.05).
At baseline, CD69 positive NK cells in HIV+/TB+ (IRIS
and non IRIS) was higher than HIV+/TB-. After 6/8
weeks of HAART, NK cells activation decreased and
there were no difference in all groups while the expres-
sion of NKG2D, NKp30, and NKp46 among NK cells in
non IRIS, but not in IRIS were higher than HIV+/TB-
[(median +1.40 vs -0.95 , p=0.03) ; (median +1.39 vs
-3.66, p=0.01) and (median -0.13 vs -3.53 , p=0.05)
respectively]. Concerning levels of NK receptors, we
observed several differences in particular NKG2C which
was higher in IRIS patients compared to non IRIS
patients at week 34.
Conclusion
Co infection with Tuberculosis in HIV infected patients
prevents NK cell degranulation reconstitution after TB
and HAART treatment.
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